<DOC>
	<DOCNO>NCT00456313</DOCNO>
	<brief_summary>This multi centre , double blind , comparator control , parallel group study determine whether asthma treatment high dose fluticasone propionate ( FP ) redirect Th2/ eosinophil response towards treatment resistant neutrophil/ monocyte response whether occurs lesser extent asthmatic subject treat combination product salmeterol fluticasone propionate ( SFC ) . The primary endpoint mean change prim blood neutrophil assess marker A17 . After run-in period 4 week subject enter 24 week high dose treatment ( FP 500 mcg bd ) 12 week medium-dose treatment FP 250 mcg bd follow 12 week treatment SFC 50/ 250 mcg . At visit lung function measurement , ACT , eNO measurement blood sample perform . A total 50 randomised subject plan recruit study</brief_summary>
	<brief_title>No Resistance After Long Term Treatment SERETIDE</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>Inclusion : Positive skin prick test History asthma ( GINA ) Regular treatment FP with/without LABA least 4 week visit 1 History recurrent episode wheezing , breathlessness , chest tightness and/ cough previous year . Able use DISKUSâ„¢ inhaler Able perform reproducible lung function test Visit 1 Inclusion criterion treatment period : FEV1 % predict &gt; 70 % ACT score &lt; 25 runin period Exclusion criterion runin period : Hospitalised asthma within 4 week prior Visit 1 Acute upper respiratory tract infection lower respiratory tract infection within 4 week prior Visit 1 Oral , parental depot corticosteroid within 4 week prior Visit 1 Hepatic impairment significant disease Exclusion criterion treatment period : Noncompliance ( &lt; 70 % )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>asthma</keyword>
	<keyword>fluticasone propionate</keyword>
	<keyword>salmeterol/fluticasone propionate</keyword>
	<keyword>combination product</keyword>
	<keyword>innate immune response</keyword>
	<keyword>neutrophil prim</keyword>
</DOC>